Skip to main content
Qiagen N.V. logo

Qiagen N.V. — Investor Relations & Filings

Ticker · QIA ISIN · NL0015001WM6 LEI · 54930036WK3GMCN17Z57 F Manufacturing
Filings indexed 626 across all filing types
Latest filing 2026-05-08 Interim / Quarterly Rep…
Country NL Netherlands
Listing F QIA

About Qiagen N.V.

https://www.qiagen.com/

Qiagen N.V. is a global provider of "Sample to Insight" solutions, offering technologies that transform biological materials into valuable molecular insights. The company develops and markets sample and assay technologies, automated instrumentation, and bioinformatics software for molecular diagnostics, applied testing, academic research, and pharmaceutical development. Its comprehensive portfolio supports the entire workflow from sample collection and preparation of DNA, RNA, and proteins to analysis and interpretation. Key product areas include sample preparation kits, PCR, digital PCR (dPCR), and next-generation sequencing (NGS) solutions, as well as syndromic testing panels for infectious diseases.

Recent filings

Filing Released Lang Actions
Q1 statement / Q1 financial report 2026
Interim / Quarterly Report Q1 2026
2026-05-08 English
QIAGEN reports full results for Q1 2026
Regulatory Filings
2026-05-07 English
Qiagen N.V., Jaarlijkse financiële verslaggeving
Annual Report FY 2025
2026-04-30 English
Ad hoc Announcement according to Art. 17 Market Abuse Regulation
Earnings Release Classification · 92% confidence The document is an ad hoc announcement under the Market Abuse Regulation that provides preliminary first-quarter results and updates to the full‐year outlook, including key sales and adjusted EPS figures, without full financial statements or detailed management discussion. This corresponds to an earnings release (initial announcement of quarterly financial results). Q1 2026
2026-04-28 English
Ad hoc Announcement according to Art. 17 Market Abuse Regulation
Earnings Release Classification · 92% confidence The document is a press release announcing QIAGEN’s preliminary Q1 2026 financial results and updated full-year outlook. It provides high-level quarterly sales, EPS outlook, segment trends, and guidance details, which is characteristic of an Earnings Release rather than a full interim report, transcript, or detailed regulatory filing. Therefore, it should be classified as an Earnings Release (ER). Q1 2026
2026-04-28 English
QIAGEN N.V.: QIAGEN announces preliminary Q1 2026 results that achieved adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook by reducing expected net sales growth and adj. EPS
Earnings Release Classification · 93% confidence The document is an ad hoc announcement under MAR Article 17, providing preliminary Q1 2026 financial results (adjusted EPS, net sales) and updating full-year outlook. It is a high-level press‐style announcement of quarterly earnings metrics rather than a detailed interim report. This matches the definition of an Earnings Release (ER). Q1 2026
2026-04-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.